Covid-19SUROCONCT04458337
SURgical Outcomes in COvid Patients - the SUROCO Multicenter Cohort Study (COVID-19)
An observational study of Covid-19 and SARS-CoV2, run by Centre hospitalier de l'Université de Montréal (CHUM) at 1 site in Canada.
Trial summary
Overall mortality of COVID-19 is variable and has been reported to be between less than 1% and 7%. Many authors around the world also reported data on hospitalization rate, need for intensive care unit (ICU) care and need for mechanical ventilation in SARS-CoV-2 infected patients. Read more about this study
- Who is it for?
- Any age
- How many people
- 318 participants
- Where
- 1 siteCanada
- Study dates
- 13 Mar 2020to 13 Apr 2022
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Study population: All patients (children and adults) confirmed being infected to SARS-CoV-2 will be included, as well as patients who have recovered, undergoing a surgical procedure in designated Canadian Centers. The investigators will include all patients up to 30th day of April 2021.
Who may be able to join
- all patients undergoing a surgery with either a SARS-CoV-2 clinical suspicion based on reported symptoms during the pandemic (fever, myalgia, fatigue, cough, dyspnea, respiratory failure, diarrhea, vomiting, abdominal pain) or without any suggestive symptoms AND a SARS-CoV-2 confirmed infection with RT-PCR before surgery or within 72 hours after surgery. Patients who have recovered from SARS-CoV-2 infection will also be included. All patients up to 30th day of April 2021 will be included.
Who cannot join
- none
Trial locations and contacts
1 site in 1 country.
Canada1 site
Centre Hospitalier de l'Université de Montréal (CHUM)
Montreal, Quebec, H2X 3E4
About this study
Official title: SURgical Outcomes in COvid Patients - the SUROCO Multicenter Cohort Study
Overall mortality of COVID-19 is variable and has been reported to be between less than 1% and 7%. Many authors around the world also reported data on hospitalization rate, need for intensive care unit (ICU) care and need for mechanical ventilation in SARS-CoV-2 infected patients. To provide anesthetic and surgical care to SARS-CoV-2 infected patients, many health workers have to organize surgical platforms, personal protections and in-hospital trajectories to prevent dissemination and cross-contamination. However, no data has been published on the surgical need of these patients, their postoperative outcomes and the impact they may have on the operating room.
Postoperative outcomes in SARS-CoV-2 infected patients seem to be variable. Expected benefits from a surgical procedure may be different in this population if their postoperative mortality is higher than expected. The association between preoperative characteristics and postoperative outcomes in this population has to be better defined.
There is a need to better quantify these and better inform use of surgical resources during a pandemic. To address this knowledge gap, the investigators propose to conduct a multicenter observational cohort study in SARS-CoV-2 infected patients undergoing a surgical procedure, as well as in those who have recovered from COVID-19.
Read the detailed description
METHODS Objectives
Primary: To describe postoperative outcomes in patients with COVID-19 undergoing a surgical procedure and measure the association between presence of symptoms and postoperative outcomes.
Secondary: To describe postoperative outcomes in patients undergoing a surgical procedure after they have healed from COVID-19 and measure the association between time from first positive test and postoperative outcomes.
Tertiary: To compare outcomes between symptomatic and asymptomatic COVID-19 patients undergoing a surgery with those who have healed from it.
Exposure variables:
For the primary objective, the exposure of interest will be the presence of symptoms at time of surgery. For the secondary objective, the exposure will be the length of time between first COVID-19 positive test and the date of surgery. For the tertiary objective, the status of the disease will be our exposure of interest.
Variable definitions:
All COVID-19 variables will be based on the first day of diagnosis (either clinical or by RT-PCR from either an oronasopharyngeal swab or an endotracheal specimen). The investigators will also capture asymptomatic SARS-CoV-2 carrier. Recovery at surgery will be defined as having two negative SARS-CoV-2 PCR tests between the last positive one and the surgery, or 1 negative test and a clinically significant period without symptoms between the last positive test and the negative one or no negative test but considered as recovered by the clinical team because of complete symptoms resolution.Criteria for "healed" status changed in November 2020 and were less restrictive (as detailed in table 1 of the protocol). No minimal or maximal delay will be applied between SARS-COV-2 infection and surgery for inclusion.
Surgical disease will be defined as the one reported by the surgeon. Surgeries will be further categorized into the following categories: neurosurgical (head, neck and spine), cardiac, thoracic, major vascular (intrathoracic and/or intra-abdominal), non-vascular abdominal (laparotomy or laparoscopy), urogenital (urology and/or gynecology), non-spine orthopedics, peripheral vascular, ENT and other. Any neurosurgical, cardiac, thoracic, major vascular or non-vascular abdominal surgery will be defined as a major surgery. The investigators will capture the surgical approach (minimally invasive or invasive) and the urgent nature of the procedure. Minimally invasive surgery will be defined as a one that does not need to open an anatomical cavity (laparoscopy, thoracoscopy, endoluminal). Urgency of surgery will be defined as one that needs to be done within 24 hours (emergent or urgent), or can wait for more than 24 hours (non-urgent).
The investigators will measure hospital survival. The investigators will also capture survival up to 30 days and 6 months using regular hospital follow-up. The investigators will use existing definitions for the postoperative pulmonary complications outcome. Non-pulmonary infectious complications will be defined as any infection that needed antibiotics for more than 72 hours. Acute kidney injury will be defined by the creatinine difference of the KDIGO-AKI criteria. Myocardial infraction and stroke will be defined as reported by treating physicians. Mechanical ventilation will be defined as any mechanical support (non-invasive or invasive). All 30-day outcomes will include any day with the outcome and the 30-day organ dysfunction free days will use existing definitions.
Sample size:
The investigators plan a convenient sample size depending on the number of patients and center included. Inclusion will start on the 13th of March 2020.
Analyses:
Primary objective The investigaors will first conduct descriptive analyses of baseline characteristics and outcomes of COVID-19 confirmed patients based on the presence of symptoms at the time of surgery (symptomatic versus asymptomatic). The investigators will report descriptively the following outcomes in both patients' population: proportion of patients with pulmonary complications, thromboembolic complications, non-pulmonary infectious complications, need for a new postoperative ICU admission, mean hospital length of stay, 30-day mechanical ventilation free-days and 30-day organ dysfunction free days. . To evaluate if presence of symptoms is associated with hospital survival in SARS-COV2 infected patients for the primary analysis, investigators will fit a multivariable Cox model that will include presence of symptoms, preoperative hospitalization, preoperative respiratory support need (invasive mechanical ventilation, oxygen therapy, no oxygen), urgency of surgery, importance of surgery (major versus minor) as independent variables and a frailty factor as a center random effect. If too few events our observed, investigators will limit covariables in their model.
Secondary objective The investigators will report descriptively patients who have recovered by categorizing them based on the time since first positive test (categorized as 0-4 weeks, 4-8 weeks and > 8 weeks). The investigators will report the same outcomes as previously mentioned. To analyze the effect of recovery time on postoperative survival, the investigators will fit a similar multivariable survival model . The investigators will include time since first positive COVID-19 test, preoperative hospitalization, preoperative respiratory support need (invasive mechanical ventilation, oxygen therapy, no oxygen), urgency of surgery, importance of surgery (major versus minor) as independent variables and a frailty factor as a center random effect. Investigators will explore non-linear relationship between time and the outcome.
Tertiary objective The investigators will report descriptively patients who have recovered and asymptomatic COVID-19 patients. To compare if those two groups of patients are different regarding hospital survival, the investigators will fit a multivariable survival model that will include status (recovered versus asymptomatic carrier), preoperative hospitalization, preoperative respiratory support need (invasive mechanical ventilation, oxygen therapy, no oxygen), urgency of surgery, importance of surgery (major versus minor) as independent variables and a frailty factor as a center random effect.
- Conditions
- Covid-19, SARS-CoV2, Surgery, Surgical Procedure; Complications, Late Effect of Complications, Postoperative Complications
- Medical subject headings
- COVID-19, Postoperative Complications
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| SARS-CoV-2 patients undergoing a surgical procedure | The investigators propose to conduct a prospective observational cohort study on all patients suspected or confirmed being infected to SARS-CoV-2, or recovered from SARS-CoV-2, undergoing a surgery. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Hospital survival
Survival was calculated from the date of participant randomization to the date of participant death due to any cause. If the participant was discharged from the hospital and not seen afterwards, the date of hospital discharge was entered as the last day seen alive.
Measured: 30 days post-operation
Secondary outcomes (12)
Occurrence of postoperative respiratory complications
The respiratory complications were recorded as diagnosed by medical personnel and/or medical imaging. The complications included atelectasis, pneumonia, acute respiratory distress syndrome (ARDS) and pulmonary aspiration.
Measured: 30 days post-operation
Occurrence of postoperative non-pulmonary infectious complications
The infection site complications were recorded as diagnosed by medical personnel and/or medical imaging. The infectious site included surgical incision or puncture site, surgical abscess, anastomotic leak, central nervous system, urinary tract infection, osteomyelitis, positive blood culture, etc. A postoperative infection had to be accompanied by an antimicrobial therapy lasting longer than 72 hours. In the event a patient suffered from two infections in the same site, both dates were recorded.
Measured: 30 days post-operation
Occurrence of acute kidney injury (AKI)
The grade of AKI was classified according to the KDIGO-AKI criteria using the highest reported creatinine or the need for new renal replacement therapy after surgery, including any mode of renal replacement therapy.
Measured: 30 days post-operation
Occurrence of postoperative thromboembolic complications
The thromboembolic complications were recorded as diagnosed by medical personnel and/or medical imaging. These included myocardial infarction, stroke, pulmonary embolism and cardiac arrest. Myocardial infarction was defined as a physician's diagnosis of a MI, which includes ST Elevation Myocardial Ischemia (STEMI) or Non-ST Elevation Myocardial Ischemia (NSTEMI).
Measured: 30 days post-operation
The need for a new postoperative ICU admission
The dates for all ICU admissions and dates of ICU discharge were recorded. If the patient was readmitted to ICU following his initial admission to ICU, the dates for admissions and discharges were recorded.
Measured: 30 days post-operation
Hospital length of stay
The number of days of hospital length of stay was calculated using the difference between the local date of discharge from the hospital and the date of hospital admission (day of surgery if ambulatory surgery). If the patient died during surgery or prior to hospital discharge, the patient's date of death was recorded as the date of discharge.
Measured: An average of 7 days
30-day mechanical ventilation free-days
The total number of days the patient was on invasive mechanical support was recorded. If mechanical ventilation was weaned and started again, the days when the patients were under mechanical ventilation were indicated. Non-invasive ventilation or high-flow nasal cannula (HFNC) were not included.
Measured: 30 days post-operation
30-day organ dysfunction free days
The total number of days the patient was: on invasive mechanical ventilator, under vasopressor therapy for more than 2 hours up to 30 days after surgery and spent under renal replacement therapy was recorded.
Measured: 30 days post-operation
Surgical reinterventions
Any surgical reintervention in the operating room either related or unrelated to the initial intervention was recorded.
Measured: 30 days post-operation
Any ICU admission during the index hospital stay
The dates for all ICU admissions and dates of ICU discharge were recorded. If the patient was admitted to ICU just after the index surgery, the date of ICU admission and time at which it occurred were recorded.
Measured: 30 days post-operation
30-day survival
Survival was calculated from the date of participant randomization to the date of participant death due to any cause, within 30 days after the surgery.
Measured: 30 days post-operation
6-month survival
Survival was calculated from the date of participant randomization to the date of participant death due to any cause, within 6 months after the surgery.
Measured: 6 months post-operation
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted7 Jul 2020
- Study start13 Mar 2020
- Primary completion13 Mar 2022
- Study completion13 Apr 2022
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Covid-19Studies of the same condition, open and under way.
- More trials run by Centre hospitalier de l'Université de Montréal (CHUM)The sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 318 participants (actual)
Sponsor and investigators
- Sponsor type
- University, hospital or other
- Collaborators
- Maisonneuve-Rosemont Hospital, Centre de recherche du Centre hospitalier universitaire de Sherbrooke, Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal, St. Justine's Hospital, Institut de Cardiologie de Montréal, McGill University Health Centre/Research Institute of the McGill University Health Centre, CHU de Quebec-Universite Laval, Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
- Responsible party
- Sponsor
- Investigators
- François-Martin Carrier, MD, FRCPC, Principal investigator, Centre hospitalier de l'Université de Montréal (CHUM)
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04458337
- Sponsor's protocol ID
- 19.386
- Acronym
- SUROCO
- Status last verified
- Sep 2021
- First submitted
- 26 Jun 2020
- Last updated
- 12 Jul 2022
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Publications
Amzallag E, Panchadsaram T, Girard M, Lecluyse V, Couture E, D'Aragon F, Kandelman S, Turgeon AF, Jodoin C, Beaulieu P, Richebe P, Carrier FM. Pulmonary complications and mortality among COVID-19 patients undergoing a surgery: a multicentre cohort study. BMJ Open. 2024 Nov 21;14(11):e090158. doi: 10.1136/bmjopen-2024-090158.
PubMed 39578040Carrier FM, Amzallag E, Lecluyse V, Cote G, Couture EJ, D'Aragon F, Kandelman S, Turgeon AF, Deschamps A, Nitulescu R, Djade CD, Girard M, Beaulieu P, Richebe P. Postoperative outcomes in surgical COVID-19 patients: a multicenter cohort study. BMC Anesthesiol. 2021 Jan 12;21(1):15. doi: 10.1186/s12871-021-01233-9.
PubMed 33435887
Study at a glance
From the registry record, last updated by the sponsor on 12 Jul 2022. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- SURgical Outcomes in COvid Patients - the SUROCO Multicenter Cohort Study
- ClinicalTrials.gov ID
- NCT04458337
- Acronym / sponsor ID
- SUROCO / 19.386
- Conditions
- Covid-19, SARS-CoV2, Surgery, Surgical Procedure; Complications, Late Effect of Complications, Postoperative Complications
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 318 participants (actual)
- Lead sponsor
- Centre hospitalier de l'Université de Montréal (CHUM)University, hospital or other
- Collaborators
- Maisonneuve-Rosemont Hospital, Centre de recherche du Centre hospitalier universitaire de Sherbrooke, Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal, St. Justine's Hospital, Institut de Cardiologie de Montréal, McGill University Health Centre/Research Institute of the McGill University Health Centre, CHU de Quebec-Universite Laval, Institut universitaire de cardiologie et de pneumologie de Québec, University Laval
- Study start
- 13 Mar 2020 (actual)
- Primary completion
- 13 Mar 2022 (actual)
- Study completion
- 13 Apr 2022 (actual)
- First posted
- 7 Jul 2020 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Overall mortality of COVID-19 is variable and has been reported to be between less than 1% and 7%. Many authors around the world also reported data on hospitalization rate, need for intensive care unit (ICU) care and need for mechanical ventilation in SARS-CoV-2 infected patients. To provide anesthetic and surgical care to SARS-CoV-2 infected patients, many health workers have to organize surgical platforms, personal protections and in-hospital trajectories to prevent dissemination and cross-contamination. However, no data has been published on the surgical need of these patients, their postoperative outcomes and the impact they may have on the operating room.
Postoperative outcomes in SARS-CoV-2 infected patients seem to be variable. Expected benefits from a surgical procedure may be different in this population if their postoperative mortality is higher than expected. The association between preoperative characteristics and postoperative outcomes in this population has to be better defined.
There is a need to better quantify these and better inform use of surgical resources during a pandemic. To address this knowledge gap, the investigators propose to conduct a multicenter observational cohort study in SARS-CoV-2 infected patients undergoing a surgical procedure, as well as in those who have recovered from COVID-19.
Detailed description
METHODS Objectives
Primary: To describe postoperative outcomes in patients with COVID-19 undergoing a surgical procedure and measure the association between presence of symptoms and postoperative outcomes.
Secondary: To describe postoperative outcomes in patients undergoing a surgical procedure after they have healed from COVID-19 and measure the association between time from first positive test and postoperative outcomes.
Tertiary: To compare outcomes between symptomatic and asymptomatic COVID-19 patients undergoing a surgery with those who have healed from it.
Exposure variables:
For the primary objective, the exposure of interest will be the presence of symptoms at time of surgery. For the secondary objective, the exposure will be the length of time between first COVID-19 positive test and the date of surgery. For the tertiary objective, the status of the disease will be our exposure of interest.
Variable definitions:
All COVID-19 variables will be based on the first day of diagnosis (either clinical or by RT-PCR from either an oronasopharyngeal swab or an endotracheal specimen). The investigators will also capture asymptomatic SARS-CoV-2 carrier. Recovery at surgery will be defined as having two negative SARS-CoV-2 PCR tests between the last positive one and the surgery, or 1 negative test and a clinically significant period without symptoms between the last positive test and the negative one or no negative test but considered as recovered by the clinical team because of complete symptoms resolution.Criteria for "healed" status changed in November 2020 and were less restrictive (as detailed in table 1 of the protocol). No minimal or maximal delay will be applied between SARS-COV-2 infection and surgery for inclusion.
Surgical disease will be defined as the one reported by the surgeon. Surgeries will be further categorized into the following categories: neurosurgical (head, neck and spine), cardiac, thoracic, major vascular (intrathoracic and/or intra-abdominal), non-vascular abdominal (laparotomy or laparoscopy), urogenital (urology and/or gynecology), non-spine orthopedics, peripheral vascular, ENT and other. Any neurosurgical, cardiac, thoracic, major vascular or non-vascular abdominal surgery will be defined as a major surgery. The investigators will capture the surgical approach (minimally invasive or invasive) and the urgent nature of the procedure. Minimally invasive surgery will be defined as a one that does not need to open an anatomical cavity (laparoscopy, thoracoscopy, endoluminal). Urgency of surgery will be defined as one that needs to be done within 24 hours (emergent or urgent), or can wait for more than 24 hours (non-urgent).
The investigators will measure hospital survival. The investigators will also capture survival up to 30 days and 6 months using regular hospital follow-up. The investigators will use existing definitions for the postoperative pulmonary complications outcome. Non-pulmonary infectious complications will be defined as any infection that needed antibiotics for more than 72 hours. Acute kidney injury will be defined by the creatinine difference of the KDIGO-AKI criteria. Myocardial infraction and stroke will be defined as reported by treating physicians. Mechanical ventilation will be defined as any mechanical support (non-invasive or invasive). All 30-day outcomes will include any day with the outcome and the 30-day organ dysfunction free days will use existing definitions.
Sample size:
The investigators plan a convenient sample size depending on the number of patients and center included. Inclusion will start on the 13th of March 2020.
Analyses:
Primary objective The investigaors will first conduct descriptive analyses of baseline characteristics and outcomes of COVID-19 confirmed patients based on the presence of symptoms at the time of surgery (symptomatic versus asymptomatic). The investigators will report descriptively the following outcomes in both patients' population: proportion of patients with pulmonary complications, thromboembolic complications, non-pulmonary infectious complications, need for a new postoperative ICU admission, mean hospital length of stay, 30-day mechanical ventilation free-days and 30-day organ dysfunction free days. . To evaluate if presence of symptoms is associated with hospital survival in SARS-COV2 infected patients for the primary analysis, investigators will fit a multivariable Cox model that will include presence of symptoms, preoperative hospitalization, preoperative respiratory support need (invasive mechanical ventilation, oxygen therapy, no oxygen), urgency of surgery, importance of surgery (major versus minor) as independent variables and a frailty factor as a center random effect. If too few events our observed, investigators will limit covariables in their model.
Secondary objective The investigators will report descriptively patients who have recovered by categorizing them based on the time since first positive test (categorized as 0-4 weeks, 4-8 weeks and > 8 weeks). The investigators will report the same outcomes as previously mentioned. To analyze the effect of recovery time on postoperative survival, the investigators will fit a similar multivariable survival model . The investigators will include time since first positive COVID-19 test, preoperative hospitalization, preoperative respiratory support need (invasive mechanical ventilation, oxygen therapy, no oxygen), urgency of surgery, importance of surgery (major versus minor) as independent variables and a frailty factor as a center random effect. Investigators will explore non-linear relationship between time and the outcome.
Tertiary objective The investigators will report descriptively patients who have recovered and asymptomatic COVID-19 patients. To compare if those two groups of patients are different regarding hospital survival, the investigators will fit a multivariable survival model that will include status (recovered versus asymptomatic carrier), preoperative hospitalization, preoperative respiratory support need (invasive mechanical ventilation, oxygen therapy, no oxygen), urgency of surgery, importance of surgery (major versus minor) as independent variables and a frailty factor as a center random effect.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| SARS-CoV-2 patients undergoing a surgical procedure | – | –The investigators propose to conduct a prospective observational cohort study on all patients suspected or confirmed being infected to SARS-CoV-2, or recovered from SARS-CoV-2, undergoing a surgery. |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
- Study population
- All patients (children and adults) confirmed being infected to SARS-CoV-2 will be included, as well as patients who have recovered, undergoing a surgical procedure in designated Canadian Centers. The investigators will include all patients up to 30th day of April 2021.
Key inclusion criteria (1 listed)
- all patients undergoing a surgery with either a SARS-CoV-2 clinical suspicion based on reported symptoms during the pandemic (fever, myalgia, fatigue, cough, dyspnea, respiratory failure, diarrhea, vomiting, abdominal pain) or without any suggestive symptoms AND a SARS-CoV-2 confirmed infection with RT-PCR before surgery or within 72 hours after surgery. Patients who have recovered from SARS-CoV-2 infection will also be included. All patients up to 30th day of April 2021 will be included.
Key exclusion criteria (1 listed)
- none
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Hospital survival
Time frame: 30 days post-operation
Survival was calculated from the date of participant randomization to the date of participant death due to any cause. If the participant was discharged from the hospital and not seen afterwards, the date of hospital discharge was entered as the last day seen alive.
12 secondary outcomes
Occurrence of postoperative respiratory complications
Time frame: 30 days post-operation
Occurrence of postoperative non-pulmonary infectious complications
Time frame: 30 days post-operation
Occurrence of acute kidney injury (AKI)
Time frame: 30 days post-operation
Occurrence of postoperative thromboembolic complications
Time frame: 30 days post-operation
The need for a new postoperative ICU admission
Time frame: 30 days post-operation
Hospital length of stay
Time frame: An average of 7 days
30-day mechanical ventilation free-days
Time frame: 30 days post-operation
30-day organ dysfunction free days
Time frame: 30 days post-operation
Surgical reinterventions
Time frame: 30 days post-operation
Any ICU admission during the index hospital stay
Time frame: 30 days post-operation
30-day survival
Time frame: 30 days post-operation
6-month survival
Time frame: 6 months post-operation
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Jul 2022.
- Derived from this study: PubMed 39578040Amzallag E, Panchadsaram T, Girard M, Lecluyse V, Couture E, D'Aragon F, Kandelman S, Turgeon AF, Jodoin C, Beaulieu P, Richebe P, Carrier FM. Pulmonary complications and mortality among COVID-19 patients undergoing a surgery: a multicentre cohort study. BMJ Open. 2024 Nov 21;14(11):e090158. doi: 10.1136/bmjopen-2024-090158.
- Derived from this study: PubMed 33435887Carrier FM, Amzallag E, Lecluyse V, Cote G, Couture EJ, D'Aragon F, Kandelman S, Turgeon AF, Deschamps A, Nitulescu R, Djade CD, Girard M, Beaulieu P, Richebe P. Postoperative outcomes in surgical COVID-19 patients: a multicenter cohort study. BMC Anesthesiol. 2021 Jan 12;21(1):15. doi: 10.1186/s12871-021-01233-9.
- Individual participant dataSharing planned: Undecided
Related trials for Covid-19
Not yet recruitingPhase 1
Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)
Post-Acute COVID-19 Syndrome
Active, not recruitingPhase 1
A Safety and Immunogenicity Trial of OCU500, ChAd36 Vector Encoding SARS-CoV-2 Spike Vaccine Via Intranasal and Inhalational Routes in Previously Vaccinated Adults
COVID-19
Active, not recruiting
Intervention to Address Disparate Mental Health Consequences of COVID-19 Pandemic on Latinx and African Newcomers
Mental Health Issue, Mental Health Disorder
Recruiting
Home-Based Exercise Tele-Rehabilitation After COVID-19
Post SARS-CoV2 (COVID-19)
Not yet recruitingPhase 1
A Safety, Reactogenicity and Immunogenicity Trial of RVX-sCPD9 Booster Intranasal COVID-19 Vaccine
COVID -19
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
François-Martin Carrier, MD, FRCPC principal investigator
Centre hospitalier de l'Université de Montréal (CHUM)
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Covid-19 and SARS-CoV2, run by Centre hospitalier de l'Université de Montréal (CHUM) at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Jul 2022. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Hospital survival (time frame: 30 days post-operation). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04458337, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jul 2022.